ZIM Laboratories Limited (ZIMLAB) Fair Value & Analysis
Healthcare · IN · Market cap ₹6.7B
Fair value as of: Jul 3, 2026
From 15 valuation models · updated today
Share price +13.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹61.49 – ₹130.48 · fair‑value band ₹17.99 – ₹23.99 · the ₹124.50 price screens above the ₹23.99 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ZIM Laboratories Limited (ZIMLAB) currently trades at ₹124.50, while our model-based Fair Value estimate is ₹23.99 — implying the stock looks roughly 80.7% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, ZIM Laboratories Limited generated revenue of ₹3.7B at a net margin of 1.6%. Revenue declined 3.2% year over year. It earns a return on equity of 2.1%. Net debt stands at ₹1.0B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
ZIM Laboratories Limited reported revenue of ₹3.7B in FY2026 versus ₹3.3B in FY2022, a compound +2.8%/yr. Reported net income was ₹58.4M in FY2026, compounding −20.4%/yr from FY2022.
Is ZIMLAB fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ZIM Laboratories Limited (ZIMLAB) undervalued?
What is the fair value of ZIMLAB?
What is the quality score of ZIMLAB?
What is the revenue of ZIM Laboratories Limited (ZIMLAB)?
What is the net profit margin of ZIMLAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.